Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16281 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Yu-Fei Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Chinese Herbal Resource Science and Engineering, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guan…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Fanconi Anemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Science and Technology Project of Binzhou Medical University, Project of South Medicine Innovation Team in Modern Agricultural Industry Technology System of Guangdong Province.
Abstract (Originalsprache)
Background and Purpose The mammalian target of rapamycin (mTOR) pathway plays critical roles in intrinsic chemoresistance by regulating Fanconi anaemia complementation group D2 (FANCD2) expression. However, the mechanisms by which mTOR regulates FANCD2 expression and related inhibitors are not clearly elucidated. Extracts of Centipeda minima ( C. minima ) showed promising chemosensitizing effects by inhibiting FANCD2 activity. Here, we have aimed to identify the bioactive chemosensitizer in C. minima extracts and elucidate its underlying mechanism. Experimental Approach The chemosensitizing effects of arnicolide C (ArC), a bioactive compound in C. minima , on non‐small cell lung cancer (NSCLC) were investigated using immunoblotting, immunofluorescence, flow cytometry, the comet assay, small interfering RNA (siRNA) transfection and animal models. The online SynergyFinder software was used to determine the synergistic effects of ArC and chemotherapeutic drugs on NSCLC cells. Key Results ArC had synergistic cytotoxic effects with DNA cross‐linking drugs such as cisplatin and mitomycin C in NSCLC cells. ArC treatment markedly decreased FANCD2 expression in NSCLC cells, thus attenuating cisplatin‐induced FANCD2 nuclear foci formation, leading to DNA damage and apoptosis. ArC inhibited the mTOR pathway and attenuated mTOR‐mediated expression of E2F1, a critical transcription factor of FANCD2 . Co‐administration of ArC and cisplatin exerted synergistic anticancer effects in the A549 xenograft mouse model by suppressing mTOR/FANCD2 signalling in tumour tissues. Conclusion and Implications ArC suppressed DNA cross‐linking drug‐induced DNA damage response by inhibiting the mTOR/E2F1/FANCD2 signalling axis, serving as a chemosensitizing agent. This provides insight into the anticancer mechanisms of ArC and offers a potential combinatorial anticancer therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Chinese Herbal Resource Science and Engineering, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Key Laboratory of Chinese Medicinal Resource from Lingnan (Guangzhou University of Chinese Medicine), Ministry of Education, Guangzhou, China.
- Institute for Inheritance-Based Innovation of Chinese Medicine, Marshall Laboratory of Biomedical Engineering, School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
- Department of Rehabilitation Medicine, Binzhou Medical University Hospital, Binzhou, China.
- Dongguan Institute of Guangzhou University of Chinese Medicine, Dongguan, China.
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Project of Binzhou Medical University
- Project of South Medicine Innovation Team in Modern Agricultural Industry Technology System of Guangdong Province
- Guangxi Natural Science Foundation
- Guangzhou Science and Technology Project
- Shenzhen Fundamental Research Program
- Basic and Applied Basic Research Foundation of Guangdong Province
- Natural Science Foundation of Guangxi Province
Zitieren
APA
Chen, Y. F., Pang, Y. C., Wang, H. C., Wu, P. E., Chen, Z. J., Huang, D., Peng, D. L., Yan, Y. M., Liu, C., Wu, L. C., Fan, X. Z., Cheng, Y. X., & Liu, Y. Q. (2024). Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer. British Journal of Pharmacology. https://doi.org/10.1111/bph.16281
Vancouver
Chen YF, Pang YC, Wang HC, Wu PE, Chen ZJ, Huang D, et al. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer. British Journal of Pharmacology. 2024. doi:10.1111/bph.16281
BibTeX
@article{Chen2024,
author = {Chen, Yu-Fei and Pang, Yan-Chun and Wang, Han-Chen and Wu, Pei-En and Chen, Zi-Jie and Huang, Da and Peng, Dong-Ling and Yan, Yong-Ming and Liu, Changhui and Wu, Li-Chuan and Fan, Xiang-Zhen and Cheng, Yong-Xian and Liu, Yong-Qiang},
title = {Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16281}
}
EUVIMED